tbuckley/cabot-search huggingface dataset:
ENDOSCOPIC MANAGEMENT OF ACCIDENTAL PORTAL VEIN PUNCTURE DURING CHOLEDOCHODUODENOSTOMY USING HOT-AXIOS LUMEN APPOSING METAL STENT
Authors: C Mangas-Sanjuan, M Bozhychko, L Compañy, F Antonio Ruiz, J Martínez Sempere, JA Casellas, J Ramón Aparicio
Journal: Endoscopy (2019)

EUS-guided cholechoduodenostomy is an endoscopic alternative technique to PTHB drainage in patients with malignant distal biliary obstruction when ERCP has failed. However, it is not well stablished how the procedure must be performed when using lumen-apposing metal stents (LAMS) and severe complications associated with the technique may occur. So our aim was to describe the endoscopic management of an accidental portal vein puncture during this procedure.
Ингибиторы протонной помпы и риск межлекарственных взаимодействий
Authors: S.M. Tkach, L.A. Onishchuk
Journal: GASTROENTEROLOGY (2020)

В статье приведены современные данные о межлекарственных взаимодействиях ингибиторов протонной помпы (ИПП) с другими препаратами. Сделан вывод о том, что риск неблагоприятных межлекарственных взаимодействий усиливается при использовании ИПП и препаратов, преимущественно метаболизирующихся цитохромным изоферментом CYP2C19. При необходимости одновременного применения ИПП со многими другими препаратами, включая клопидогрель, предпочтение следует отдавать пантопразолу.
Abstract 3605: The role of androgen receptor in invasive lobular breast carcinoma
Authors: Hillary Stires, Rebecca B. Riggins
Journal: Cancer Research (2017)

Abstract The leading problem for women with estrogen receptor α (ER) breast cancer – approximately 70% of all breast cancers – is that while the majority of tumors initially respond to anti-estrogen treatment including Tamoxifen and aromatase inhibitors, they will develop endocrine resistance. A histological subset of breast cancer called invasive lobular carcinoma (ILC) accounts for 15% of all breast cancer cases and approximately 90% of ILC are ER-positive. Despite clinical markers suggesting a better prognosis for ILC compared to the more common invasive ductal carcinoma (IDC), recent data suggests women with ILC develop Tamoxifen resistance at a higher rate than IDC. New strategies for treating hormone refractory tumors are needed that not only overcome anti-estrogen resistance, but also present a more tolerable side effect profile and have fewer dose-limiting toxicities than adjuvant chemotherapy. The majority of ER-positive breast cancers also express androgen receptor (AR) and while AR presence in breast cancer is controversial, increased expression of AR leads to Tamoxifen resistance in IDC cell lines. Since ILC has more AR expression than IDC, the role of AR in ILC was studied by treating cells with the non-aromatizable androgen dihydrotestosterone (DHT) and the synthetic androgen R1881 as well as the anti-androgen Enzalutamide. We have previously begun to characterize a Tamoxifen resistant variant of the ILC cell line Sum44PE termed LCCTam cells. In both Sum44PE and LCCTam cells, AR protein expression increases in response to androgens, an action that is blocked by Enzalutamide. Interestingly, androgens do not promote growth in ILC cells, but Enzalutamide is still able to inhibit growth. These results suggest Enzalutamide may be an effective alternative therapy for women with ILC. Future studies will focus on whether regulation of nuclear receptor co-factors influences differences in AR signaling in ILC. Citation Format: Hillary Stires, Rebecca B. Riggins. The role of androgen receptor in invasive lobular breast carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3605. doi:10.1158/1538-7445.AM2017-3605
In Teens with Severe Obesity, Can Bariatric Surgery Wait until Adulthood?
Authors: Ted D Adams
Journal: New England Journal of Medicine (2019)

Conventionally, physiological and psychological differences between children and adults have directed their clinical care pathways, including treatment strategies, physician specialties, and health care facilities. One exception that has occurred gradually over the past few decades relates to the prevention and treatment of obesity. Striking similarities in obesity among adults, children, and adolescents have emerged — specifically, the increasing prevalence of obesity, multiple obesity-related coexisting conditions (medical, social, and psychological), and evolving methods of treatment.1-3 In addition, most adolescents who are obese remain obese as adults,4 and adults with obesity who were obese as adolescents have worse medical outcomes than persons . . .
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
Authors: K. Hastings, H.A. Yu, W. Wei, F. Sanchez-Vega, M. DeVeaux, J. Choi, H. Rizvi, A. Lisberg, A. Truini, C.A. Lydon, Z. Liu, B.S. Henick, A. Wurtz, G. Cai, A.J. Plodkowski, N.M. Long, D.F. Halpenny, J. Killam, I. Oliva, N. Schultz, G.J. Riely, M.E. Arcila, M. Ladanyi, D. Zelterman, R.S. Herbst, S.B. Goldberg, M.M. Awad, E.B. Garon, S. Gettinger, M.D. Hellmann, K. Politi
Journal: Annals of Oncology (2019)

BackgroundAlthough EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however, there is a lack of understanding of the characteristics of EGFR mutant lung tumors responsive to immune checkpoint blockade.Patients and methodsWe retrospectively analyzed de-identified clinical and molecular data on 171 cases of EGFR mutant lung tumors treated with immune checkpoint inhibitors from the Yale Cancer Center, Memorial Sloan Kettering Cancer Center, University of California Los Angeles, and Dana Farber Cancer Institute. A separate cohort of 383 EGFR mutant lung cancer cases with sequencing data available from the Yale Cancer Center, Memorial Sloan Kettering Cancer Center, and The Cancer Genome Atlas was compiled to assess the relationship between tumor mutation burden and specific EGFR alterations.ResultsCompared with 212 EGFR wild-type lung cancers, outcomes with programmed cell death 1 or programmed death-ligand 1 (PD-(L)1) blockade were worse in patients with lung tumors harboring alterations in exon 19 of EGFR (EGFRΔ19) but similar for EGFRL858R lung tumors. EGFRT790M status and PD-L1 expression did not impact response or survival outcomes to immune checkpoint blockade. PD-L1 expression was similar across EGFR alleles. Lung tumors with EGFRΔ19 alterations harbored a lower tumor mutation burden compared with EGFRL858R lung tumors despite similar smoking history.ConclusionsEGFR mutant tumors have generally low response to immune checkpoint inhibitors, but outcomes vary by allele. Understanding the heterogeneity of EGFR mutant tumors may be informative for establishing the benefits and uses of PD-(L)1 therapies for patients with this disease.
Rat Organic Anion Transport Protein 1A1 Interacts Directly With Organic Anion Transport Protein 1A4 Facilitating Its Maturation and Trafficking to the Hepatocyte Plasma Membrane
Authors: Pijun Wang, Wen‐Jun Wang, Jo Choi‐Nurvitadhi, Yaniuska Lescaille, John W. Murray, Allan W. Wolkoff
Journal: Hepatology (2019)

Organic anion transport proteins (OATPs) on the basolateral surface of hepatocytes mediate uptake of a number of drugs and endogenous compounds. Previous studies showed that rat OATP1A1 (rOATP1A1) has a postsynaptic density protein, drosophila disc large tumor suppressor, zonula occludens‐1 protein (PDZ) consensus binding motif at its C‐terminus and binds to PDZ domain containing 1 (PDZK1), which is required for its cell‐surface localization. PDZK1 associates with rOATP1A1‐containing endocytic vesicles within cells, mediating recruitment of motor proteins required for microtubule‐based trafficking to the plasma membrane. rOATP1A4 also traffics to the plasma membrane, although it lacks a PDZ binding consensus sequence. The current study was designed to test the hypothesis that trafficking of rOATP1A4 to the plasma membrane requires its direct interaction with rOATP1A1 resulting in a complex that traffics through the cell in common subcellular vesicles in which the cytosolic tail of rOATP1A1 is bound to PDZK1. We found that 74% of rOATP1A4‐containing rat liver endocytic vesicles (n = 12,044) also contained rOATP1A1. Studies in transfected HEK293 cells showed surface localization of rOATP1A1 only when coexpressed with PDZK1 whereas rOATP1A4 required coexpression with rOATP1A1 and PDZK1. Studies in stably transfected HeLa cells that constitutively expressed PDZK1 showed that coexpression of rOATP1A4 with rOATP1A1 resulted in more rapid appearance of rOATP1A4 on the plasma membrane and faster maturation to its fully glycosylated form. Similar results were observed on immunofluorescence analysis of single cells. Immunoprecipitation of rat liver or transfected HeLa cell lysates with rOATP1A1 antibody specifically co‐immunoprecipitated rOATP1A4 as determined by western blotting. Conclusion: These studies indicate that optimal rOATP1A4 trafficking to the cell surface is dependent upon coexpression and interaction with rOATP1A1. As rOATP1A1 binds to the chaperone protein, PDZK1, rOATP1A4 functionally hitchhikes through the cell with this complex.
GASTRIC POLYPS: VARYING PATTERN OF EPIDEMIOLOGIC AND PHENOTYPIC CHARACTERISTICS BETWEEN 2003 – 2010 AND 2010 – 2017
Authors: P Kourkoulis, C Kapizioni, A Mellos, P Giannelis, G Koutoufaris, K Milioni, E Xourgia, K Makris, V Ntouli, G Michalopoulos, S Vrakas, V Xourgias
Journal: Endoscopy (2019)

Epidemiologic and phenotypic characteristics of gastric polyps are directly associated to Proton Pump Inhibitors (PPI) use and Helicobacter pylori (Hp) infection. Aim of this study was to outline any changes of these parameters during different time periods.
Long-Acting Reversible Contraceptive Methods Need a Barrier to Prevent Sexually Transmitted Infections in Adolescents
Authors: Andrea J. Hoopes, Gina S. Sucato
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Task sharing with non-physician health-care workers for management of blood pressure in low-income and middle-income countries: a systematic review and meta-analysis
Authors: T N Anand, Linju Maria Joseph, A V Geetha, Dorairaj Prabhakaran, Panniyammakal Jeemon
Journal: The Lancet Global Health (2019)

Task sharing for the management of hypertension could be useful for understaffed and resource-poor health systems. We assessed the effectiveness of task-sharing interventions in improving blood pressure control among adults in low-income and middle-income countries.
Intérêt de l'endoscopie digestive dans le diagnostic étiologique des thromboses veineuses profondes
Authors: A Ouni, L Hamzaoui, B Hasnaoui, M Mahmoudi, M Medhioub, A Khsiba, MM Azouz
Journal: Endoscopy (2019)

Les gastroentérologues sont souvent sollicités pour la réalisation d'une endoscopie digestive haute ou d'une coloscopie dans le cadre du bilan étiologique des thromboses veineuses profondes et ce afin de rechercher particulièrement une tumeur primitive digestive. Cependant, l'apport de ces examens n'est pas connu dans cette indication.
PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy
Authors: Anna G Turkina, Oleg Shukhov, Ekaterina Chelysheva, Irina Nemchenko, Anna Petrova, Anastasiya Bykova, Andrey Zaritskey, Elza Lomaia, Vasily Shuvaev, Fedor Novikov, Veronika Shulgina, Ghermes Chilov
Journal: Blood (2017)
BURNING DOWN THE HOUSE: DOES ENDOSCOPIC BAND LIGATION FOR THE TREATMENT OF GAVE RESULT IN BETTER OUTCOMES COMPARED TO ARGON PHOTO COAGULATION?
Authors: N O'Morain, H O'Donovon, C Conlon, V Warner, E Shannon, E Slattery
Journal: Endoscopy (2019)

Gastric antral vascular ectasia (GAVE) is a rare vascular malformation located primarily in the antrum. While Argon Photo Coagulation (APC) is the current standard of care, Endoscopic Band Ligation (EBL) is increasingly used. There is currently no consensus regarding the optimal treatment modality, as current available evidence is limited to small case series. We aimed to compare outcomes following each treatment modality.
Quality Measures, All‐Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis
Authors: Marina Serper, David E. Kaplan, Justine Shults, Peter P. Reese, Lauren A. Beste, Tamar H. Taddei, Rachel M. Werner
Journal: Hepatology (2019)

Decompensated cirrhosis is associated with high morbidity and mortality. However, no standardized quality measures (QMs) have yet been adopted widely. The Veterans Affairs (VA) Advanced Liver Disease Technical Advisory Group recently developed a set of six internal QMs to guide quality improvement efforts in cirrhosis in the domains of access to care, hepatocellular carcinoma surveillance, variceal surveillance, quality of inpatient care for upper gastrointestinal bleeding, and cirrhosis-related rehospitalizations. We aimed to (1) quantify adherence to cirrhosis QMs and (2) determine whether adherence was associated with all-cause mortality and health care use within a large national cohort of veterans with cirrhosis. We performed a retrospective study using data from the Veterans Outcomes and Costs Asociated with Liver Disease cohort of 121,129 patients newly diagnosed with cirrhosis from January 1, 2008, to December 31, 2016, at 128 VA facilities. The mean follow-up time was 2.7 years (interquartile range, 1.1-5.1 years). Adherence to outpatient access to specialty care was 71%, variceal surveillance was 32%, and early postdischarge care was 54%. In adjusted analyses, outpatient access to specialty care (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.78-0.82), hepatocellular carcinoma surveillance (HR, 0.92; 95% CI, 0.90-0.95), variceal surveillance (HR, 0.93; 95% CI, 0.89-0.99), and early postdischarge care (HR, 0.57; 95% CI, 0.54-0.60) were associated with lower all-cause mortality. Readmissions after 30 days (HR, 1.53; 1.46-1.60) and 90 days (HR, 1.88; 95% CI, 1.54-1.70) were associated with higher all-cause mortality. Higher adherence to QMs was also associated with lower inpatient health care use. Conclusion: Five of the six proposed VA cirrhosis QMs were measurable using existing data sources, associated with mortality and health care use, and may be used to guide future quality improvement efforts in cirrhosis.
ENDOSCOPIC TREATMENT OF A DIVERTICULAR OESOPHAGEAL DUPLICATION
Authors: P Familiari, R Landi, G Gibiino, F Mangiola, F D'Aversa, V Bove, I Boskoski, V Perri, A Tringali, G Costamagna
Journal: Endoscopy (2019)

Oesophageal duplications are rare congenital malformations, presenting as cystic, tubular or diverticular. Oesophageal duplications can remain asymptomatic for decades, and clinical manifestations can occur at any moment.
PREDICTIVE MODEL FOR NON-NEOPLASTIC PATHOLOGY RESULTS AFTER ENDOSCOPIC RESECTION OF EARLY GASTRIC CANCER
Authors: CH Kim
Journal: Endoscopy (2019)

Rate of non-neoplastic pathology (NNP) results after endoscopic resection (ER) of gastric epithelial neoplasia (GEN) has been reported as 3˜7%. However, pretreatment characteristics for NNP results have not been identified to date. The aim of this study was to develop a predictive model for NNP results after ER.
Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma
Authors: Lauren Lupino, Tracey Perry, Sandra Margielewska, Robert Hollows, Maha Ibrahim, Matthew Care, Jeremy Allegood, Reuben Tooze, Roger Sabbadini, Gary Reynolds, Roy Bicknell, Zbigniew Rudzki, Ye Lin Hock, Ulises Zanetto, Wenbin Wei, William Simmons, Sarah Spiegel, Ciaran B. J. Woodman, Martin Rowe, Katerina Vrzalikova, Paul G. Murray
Journal: Leukemia (2019)

Abstract Although the over-expression of angiogenic factors is reported in diffuse large B-cell lymphoma (DLBCL), the poor response to anti-VEGF drugs observed in clinical trials suggests that angiogenesis in these tumours might be driven by VEGF-independent pathways. We show that sphingosine kinase-1 (SPHK1), which generates the potent bioactive sphingolipid sphingosine-1-phosphate (S1P), is over-expressed in DLBCL. A meta-analysis of over 2000 cases revealed that genes correlated with SPHK1 mRNA expression in DLBCL were significantly enriched for tumour angiogenesis meta-signature genes; an effect evident in both major cell of origin (COO) and stromal subtypes. Moreover, we found that S1P induces angiogenic signalling and a gene expression programme that is present within the tumour vasculature of SPHK1-expressing DLBCL. Importantly, S1PR1 functional antagonists, including Siponimod, and the S1P neutralising antibody, Sphingomab, inhibited S1P signalling in DLBCL cells in vitro. Furthermore, Siponimod, also reduced angiogenesis and tumour growth in an S1P-producing mouse model of angiogenic DLBCL. Our data define a potential role for S1P signalling in driving an angiogenic gene expression programme in the tumour vasculature of DLBCL and suggest novel opportunities to target S1P-mediated angiogenesis in patients with DLBCL.
Abstract 1003: Extranuclear ERα-mTOR signaling rewires cancer cell metabolism during obesity-associated breast cancer
Authors: Zeynep Madak Erdogan, Yiru C. Zhao, Gianluigi Rossi, Kinga Wrobel, Eylem Kulkoyluoglu, Sung Hoon Kim, John A. Katzenellenbogen, Jodi Flaws, Rebecca Smith
Journal: Cancer Research (2017)

Abstract Obesity is a preventable risk factor for post-menopausal ERα-(+) breast cancer. We hypothesized that serum from obese post-menopausal women contain factors that would increase tumorigenicity of breast cancer cells and increase risk of ERα-(+) breast cancer. Using whole metabolite profiling and OLINK biomarker panel of about 400 proteins associated with cancer, inflammation and cardiovascular disease, we identified biomarkers that were differentially present in serum from 50 obese v.s. 50 non-obese postmenopausal women. Next, using in vitro cell based assays as proxy we identified certain free fatty acids (FFAs) as factors from serum that correlate with increased cell proliferation, motility and mTOR activation in ERα(+) breast cancer cells. We performed RNA-Seq, ERα ChIP-Seq and metabolomics analysis in breast cancer cells that are exposed to conditions that mimic serum from obese postmenopausal women. This integrative -omics approach enabled us to uncover ERα and mTOR pathway-dependent metabolic rewiring in breast cancer cells under these conditions. Pathway preferential estrogens (PaPEs), which target ERα and mTOR signaling, were able to block free fatty acid-dependent proliferation of breast cancer cells. In fact, efficient cancer cell killing by PaPEs was achieved only in the presence of FFAs, suggesting a role for obesity-associated metabolic rewiring in providing new vulnerabilities for the breast cancer cells. In summary, we uncovered a novel role for extranuclear-initiated ERα signaling in rewiring breast cancer cell metabolism in response to obesity-associated factors in the serum. Our findings provide a basis for preventing or inhibiting obesity-associated breast cancer by using PaPEs that would exploit new metabolic vulnerabilities of breast tumors in obese postmenopausal women. Citation Format: Zeynep Madak Erdogan, Yiru C. Zhao, Gianluigi Rossi, Kinga Wrobel, Eylem Kulkoyluoglu, Sung Hoon Kim, John A. Katzenellenbogen, Jodi Flaws, Rebecca Smith. Extranuclear ERα-mTOR signaling rewires cancer cell metabolism during obesity-associated breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1003. doi:10.1158/1538-7445.AM2017-1003
Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Authors: Sneha Ramakrishna, Steven L. Highfill, Zachary Walsh, Sang M. Nguyen, Haiyan Lei, Jack F. Shern, Haiying Qin, Ira L. Kraft, Maryalice Stetler-Stevenson, Constance M. Yuan, Jennifer D. Hwang, Yang Feng, Zhongyu Zhu, Dimiter Dimitrov, Nirali N. Shah, Terry J. Fry
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Chimeric antigen receptor T-cell (CART) therapy targeting CD22 induces remission in 70% of patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, the majority of post-CD22 CART remissions are short and associated with reduction in CD22 expression. We evaluate the implications of low antigen density on the activity of CD22 CART and propose mechanisms to overcome antigen escape. Experimental Design: Using ALL cell lines with variable CD22 expression, we evaluate the cytokine profile, cytotoxicity, and in vivo CART functionality in the setting of low CD22 expression. We develop a high-affinity CD22 chimeric antigen receptor (CAR) as an approach to improve CAR sensitivity. We also assess Bryostatin1, a therapeutically relevant agent, to upregulate CD22 and improve CAR functionality. Results: We demonstrate that low CD22 expression negatively impacts in vitro and in vivo CD22 CART functionality and impairs in vivo CART persistence. Moreover, low antigen expression on leukemic cells increases naïve phenotype of persisting CART. Increasing CAR affinity does not improve response to low-antigen leukemia. Bryostatin1 upregulates CD22 on leukemia and lymphoma cell lines for 1 week following single-dose exposure, and improves CART functionality and in vivo persistence. While Bryostatin1 attenuates IFNγ production by CART, overall in vitro and in vivo CART cytotoxicity is not adversely affected. Finally, administration of Bryostain1 with CD22 CAR results in longer duration of in vivo response. Conclusions: We demonstrate that target antigen modulation is a promising strategy to improve CD22 CAR efficacy and remission durability in patients with leukemia and lymphoma. See related commentary by Guedan and Delgado, p. 5188
Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways
Authors: Evan Der, Hemant Suryawanshi, Pavel Morozov, Manjunath Kustagi, Beatrice Goilav, Saritha Ranabothu, Peter Izmirly, Robert Clancy, H. Michael Belmont, Mordecai Koenigsberg, Michele Mokrzycki, Helen Rominieki, Jay A. Graham, Juan P. Rocca, Nicole Bornkamp, Nicole Jordan, Emma Schulte, Ming Wu, James Pullman, Kamil Slowikowski, Soumya Raychaudhuri, Joel Guthridge, Judith James, Jill Buyon, Thomas Tuschl, Chaim Putterman
Journal: Nature Immunology (2019)